Navigation Links
Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
Date:7/23/2008

se in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule called Trp-p8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.

Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties surrounding the efficacy of PROVENGE to treat men suffering from prostate cancer, risks and uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such differences include risks related to our limited operating history, risks associated with completing our clinical trials, the risk that the safety and/or efficacy results of existing clinical trials or from additional clinical trials for PROVENGE will not support approval for a biologics license, the risk that the FDA may interpret data differently than we do or require more data or a more rigorous analysis of data than expected, the risk that the FDA will not approve a product for which a biologics license has been applied, the risk that the results of a clinical trial for PROVENGE or other product may not be indicative of results obtained in a later clinical trial, risks that we may lack the financial resources and access to capital to fund required clinical trials or commercialization of PROVENGE, our dependence on the efforts of third pa
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
3. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
4. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
5. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
6. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
7. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
8. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
9. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
10. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
11. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... SYDNEY and SOUTHAMPTON , ... -- Australian pharmaceutical company Pharmaxis Ltd (ASX: PXS) and UK biotechnology ... into a research collaboration to develop a selective inhibitor to ... fatal lung disease idiopathic pulmonary fibrosis (IPF). ... US. Current products are expected to produce global revenues in ...
(Date:8/4/2015)... VIEW, Calif. , Aug. 4, 2015  IRIDEX ... James H. Mackaness , who had served as chief ... since 2012, has resigned his positions with the Company, ... officer position at another company. Mr. Mackaness intends to ... Company,s second quarter earnings announcement and 10-Q filing. ...
(Date:8/4/2015)...   Regulus Therapeutics Inc . (NASDAQ: ... and development of innovative medicines targeting microRNAs, today ... ended June 30, 2015 and provided a summary ... second quarter of 2015 and recent period marked ... Paul Grint, M.D., President and CEO of Regulus. ...
Breaking Medicine Technology:Pharmaxis and Synairgen Announce Research Collaboration to Develop LOXL2 Inhibitor For Pulmonary Fibrosis 2Pharmaxis and Synairgen Announce Research Collaboration to Develop LOXL2 Inhibitor For Pulmonary Fibrosis 3IRIDEX Chief Financial Officer Resigns to Accept Another Opportunity 2Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 2Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 3Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 4Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 5Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 6Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 7Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 8Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 9Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 10
... MedShape Solutions, Inc., the industry leader in innovative ... DynaNail™ Intramedullary Ankle Fusion Nail. Ankle fusion is ... degenerative ankle joints, to correct joint deformities or ... unique, patented design utilizes shape memory alloy technology ...
... Aug. 9, 2011 Reportlinker.com announces that ... in its catalogue: Medical ... Trends - Q2 2011 ... Quarterly Deals Analysis: M&A and Investment Trends ...
Cached Medicine Technology:MedShape Solutions Announces FDA 510(k) Clearance of Innovative Ankle Fusion Device 2MedShape Solutions Announces FDA 510(k) Clearance of Innovative Ankle Fusion Device 3Medical Equipment Quarterly Deals Analysis: M&A and Investment Trends - Q2 2011 2Medical Equipment Quarterly Deals Analysis: M&A and Investment Trends - Q2 2011 3Medical Equipment Quarterly Deals Analysis: M&A and Investment Trends - Q2 2011 4Medical Equipment Quarterly Deals Analysis: M&A and Investment Trends - Q2 2011 5Medical Equipment Quarterly Deals Analysis: M&A and Investment Trends - Q2 2011 6Medical Equipment Quarterly Deals Analysis: M&A and Investment Trends - Q2 2011 7Medical Equipment Quarterly Deals Analysis: M&A and Investment Trends - Q2 2011 8Medical Equipment Quarterly Deals Analysis: M&A and Investment Trends - Q2 2011 9Medical Equipment Quarterly Deals Analysis: M&A and Investment Trends - Q2 2011 10Medical Equipment Quarterly Deals Analysis: M&A and Investment Trends - Q2 2011 11Medical Equipment Quarterly Deals Analysis: M&A and Investment Trends - Q2 2011 12
(Date:8/5/2015)... , ... August 05, 2015 , ... ... have just published updated guidelines for the management of malignant pleural mesothelioma. Details ... to read the article. , The updated guidelines issued by the European ...
(Date:8/5/2015)... ... August 05, 2015 , ... Friendly Smiles Dental ... practice; Dr. Daniel H. Huynh, DMD and Dr. Michael J. Foley, DMD. The full ... patients at all three location in the Tampa Bay area, where Friendly Smiles Dental ...
(Date:8/5/2015)... ... ... Social Security benefits are not keeping pace with rising household budgets, according ... Citizens League (TSCL). The record low growth in cost-of-living adjustments (COLAs) in recent ... age 65 and older, says TSCL. , When asked to select between four statements ...
(Date:8/5/2015)... ... , ... Stelari introduces their new collection, The Earth’s Song, inspired by the ... Earth’s Song. Combining fashion and activewear, Stelari’s new collection let’s you take your bohemian ... this collection is sure to make the spirit seeker swoon with prints as meaningful ...
(Date:8/5/2015)... ... ... A leader in Primary Care Continuing Medical Education (CME), Continuing Education ... as its new Director of Program Management. , Su has over 16 years experience ... Primary Care Network (PCN) as the Director, Program Implementation as well as Supervisor of ...
Breaking Medicine News(10 mins):Health News:New Mesothelioma Treatment Guidelines Issued By European Researchers, According to Surviving Mesothelioma 2Health News:Friendly Smiles Dental Care Welcomes New Doctors 2Health News:Majority of Older Americans Say Social Security Benefits Not Keeping up with Rising Household Costs, According to a New Survey from the Senior Citizens League 2Health News:Majority of Older Americans Say Social Security Benefits Not Keeping up with Rising Household Costs, According to a New Survey from the Senior Citizens League 3Health News:Stelari: Bohemian Chic Activewear Line 2Health News:Stelari: Bohemian Chic Activewear Line 3Health News:Leading Continuing Medical Education (CME) Provider, Continuing Education Company (CEC), hires expert Su Barnwell as Director of Program Management 2Health News:Leading Continuing Medical Education (CME) Provider, Continuing Education Company (CEC), hires expert Su Barnwell as Director of Program Management 3
... Cancer At All Stages Steps Away From Home, ... ... Medical University of,South Carolina (MUSC) Foundation for Research and Development announced ... for bladder cancer have shown to be accurate for only 40 ...
... of,National Problem Gambling Awareness Week, the state departments ... of counseling,and treatment services available to those affected ... not only the gambler but also their family,and ... Commonwealth,of Pennsylvania is committed to addressing compulsive gambling ...
... 10 Medco Health,Solutions, Inc. (NYSE: MHS ) ... follows:, On Monday, March 17, 2008, Timothy C. ... Inc., Medco,s specialty pharmacy,subsidiary, is scheduled to address the ... at the Boston Marriott Copley,Place will begin at 1:45 ...
... health insurance programs do not provide coverage to international ... ... Seven Corners, one of the,industry,s most experienced travel health insurance ... they,plan to travel abroad for spring break vacations. Most health insurance,programs ...
... be getting them, study says , , MONDAY, March 10 (HealthDay ... choices for kidney cancer more than clinical factors such as ... finds. , This means many patients who are candidates ... where only part of the kidney is removed, may not ...
... ZARS Pharma, Inc. announced,today the completion of ... promotion and distribution rights for all markets ... (lidocaine and tetracaine) Cream,7%/7%, a topical anesthetic ... patients undergoing potentially painful cosmetic and other,skin ...
Cached Medicine News:Health News:Cell Receptor on Track for Painless Bladder Cancer Test 2Health News:State Agencies Highlight Available Assistance During Problem Gambling Awareness Week 2Health News:Medco to Present at Cowen and Company and Lehman Brothers Health Care Conferences 2Health News:Seven Corners Alerts Spring Breakers that They Need Travel Insurance to Vacation Abroad 2Health News:Seven Corners Alerts Spring Breakers that They Need Travel Insurance to Vacation Abroad 3Health News:Surgeon's Preferences Dictate Choice of Kidney Cancer Surgery 2Health News:Surgeon's Preferences Dictate Choice of Kidney Cancer Surgery 3Health News:ZARS Pharma Announces Worldwide License Agreement With Galderma Pharma S.A. for Pliaglis(TM), a Topical Local Anesthetic 2Health News:ZARS Pharma Announces Worldwide License Agreement With Galderma Pharma S.A. for Pliaglis(TM), a Topical Local Anesthetic 3
... Intuitive Operation for the High Speed ... Special Modules for Additional Requirements and ... for and with ophthalmologists. Important for ... guaranteed by short operating sequences. Extensive ...
... modular designed, upgradable ultrasonic pachometer offering ... accurate reproducible corneal thickness measurements for ... The unit employs a sleek design ... economical pachometer or a full control ...
... This unique system uses prolene as thread-guide reducing ... hollow Ritleng Probe is inserted into the nasolacrimal ... through it. The probe is then withdrawn leaving ... 0.64 mm diam silicone tubing into place. Newly ...
... Optimal temporary implant for use with patients ... pupil dilator type 5S is a semicircular ... the pupil during phacoemulsification. It is supplied ... Indication: Expansion of the pupil during phacoemulsification ...
Medicine Products: